[Retracted] Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer

Table 3

The AEs of HER2-positive breast cancer patients [ (%)].

AEs	Grade			Total
	1	2	≥3
Hematological AEs
Anemia	3	2	0	5
Neutropenia	0	2	3	5
Thrombocytopenia	0	0	1	1
Non-hematological AEs
Diarrhea	19	3	3	25
Vomiting	1	0	0	1
Skin rash	2	0	0	2
Hand-foot syndrome	2	0	0	2
Other AEs
Elevated transaminase	1	0	0	1
Hypertension	3	0	0	3
Peripheral neuritis	2	1	0	3